Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.

Japanese journal of clinical oncology - 4 Feb 2017

Yoshihama Tomoko, Hirasawa Akira, Nomura Hiroyuki, Akahane Tomoko, Nanki Yoshiko, Yamagami Wataru, Kataoka Fumio, Tominaga Eiichiro, Susumu Nobuyuki, Mushiroda Taisei, Aoki Daisuke

Abstract excerpt

We investigated whether UGT1A1 polymorphisms are associated with the prognosis of ovarian cancer patients treated with irinotecan. UGT1A1 genotypes were analyzed in 11 stage I ovarian clear cell carcinoma patients who received irinotecan as first-line therapy. Progression-free survival, overall survival and adverse events were also assessed for each genotype. Three patients harbored UGT1A1*1/*6 while another...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Neoplasm Staging

Share to Ovarian Neoplasms

Share to Prognosis

Source

Identifiers

PMID: 28173214
DOI: 10.1093/jjco/hyw163

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.PMID 28173214Read ↗

UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.Semantic proximity Read ↗

Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Semantic proximity Read ↗

Pharmacogenetics of irinotecan toxicitySemantic proximity Read ↗

UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapySemantic proximity Read ↗

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.Semantic proximity Read ↗

A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.Semantic proximity Read ↗

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.Semantic proximity Read ↗

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.Semantic proximity Read ↗

Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.Semantic proximity Read ↗

The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.